Avoiding Overtreatment of Ductal Carcinoma in situ

Carolien L van der Borden; Saskia Stoffers; Esther H Lips; Jelle Wesseling

doi:10.1016/j.trecan.2019.05.005

Avoiding Overtreatment of Ductal Carcinoma in situ

Trends Cancer. 2019 Jul;5(7):391-393. doi: 10.1016/j.trecan.2019.05.005. Epub 2019 Jun 20.

Authors

Carolien L van der Borden¹, Saskia Stoffers¹, Esther H Lips¹, Jelle Wesseling²

Affiliations

¹ Division of Molecular Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
² Division of Molecular Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Division of Diagnostic Oncology, Department of Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Electronic address: j.wesseling@nki.nl.

PMID: 31311652
DOI: 10.1016/j.trecan.2019.05.005

Abstract

Ductal carcinoma in situ (DCIS), a precursor to invasive breast cancer (IBC), represents 25% of all breast neoplasms. Most are harmless, but some progress to IBC. Yet, almost all DCIS are treated. Learning how to distinguish harmless from hazardous DCIS will save many women with harmless DCIS the burden of overtreatment.

Keywords: breast cancer; ductal carcinoma in situ; overdiagnosis; overtreatment; screening.

Publication types

Letter

MeSH terms

Breast Neoplasms / diagnosis
Breast Neoplasms / mortality
Breast Neoplasms / therapy*
Carcinoma, Intraductal, Noninfiltrating / diagnosis
Carcinoma, Intraductal, Noninfiltrating / mortality
Carcinoma, Intraductal, Noninfiltrating / therapy*
Combined Modality Therapy / adverse effects
Combined Modality Therapy / methods
Disease Management
Disease Progression
Early Detection of Cancer
Female
Humans
Medical Overuse / prevention & control*
Prognosis
Risk
Treatment Outcome